{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T20:48:19Z","timestamp":1740170899867,"version":"3.37.3"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"3-4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Austere clinical settings, including remote military installations, face unique challenges in screening pregnant women for aneuploidy. The objective of this study was to compare the direct and indirect prenatal costs of traditional 2-part serum-based screening to cell-free DNA (cfDNA) for detection of trisomies 18 and 21 for a military treatment facility with limited in-house perinatal resources.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We identified Naval Hospital Guantanamo Bay as a surrogate for an austere clinical environment. A prenatal cost of care analysis incorporating direct and indirect expenses was performed to compare the 2 aneuploidy screening strategies for a theoretical cohort of 100 patients for detection of trisomies 18 and 21. The baseline aneuploidy uptake rate was determined using a historical cohort. Test performance characteristics were obtained from the contracting laboratory. Aneuploidy rates and costs were calculated using previously published data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Assuming a baseline screen uptake rate of 87%, initial screening using the traditional approach would directly cost $8,285.01 versus $44,140.32 with cfDNA. Considering indirect costs such as travel, consultative services, evaluation and follow-up testing of an abnormal screen result, and lost productivity, the cost difference narrows to $14,458.25 over a 5- to 6-year period. Cost equivalence is achieved when cfDNA is priced at $341.17 per test.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Cell-free DNA as an initial screening strategy offers enhanced detection rates for trisomies 18 and 21 but remains more costly than traditional screening when incorporating direct and indirect expenses. In a low volume setting with limited resources, the added cost may be justified given the implications of unrecognized aneuploidy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/milmed\/usaa375","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T03:46:28Z","timestamp":1607312788000},"page":"e410-e414","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing Fetal Aneuploidy Screening in an Austere Military Clinical Environment: A Prenatal Cost Comparison"],"prefix":"10.1093","volume":"186","author":[{"given":"Ashton D","family":"Burrus","sequence":"first","affiliation":[{"name":"School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M","family":"Shaw-Williams","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, Naval Medical Center Portsmouth, Portsmouth, VA 23708, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5545-7361","authenticated-orcid":false,"given":"Andrew S","family":"Thagard","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, Naval Medical Center Portsmouth, Portsmouth, VA 23708, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"2021022616411911100_R1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004084","article-title":"American College of Obstetricians and Gynecologists\u2019 Committee on Practice Bulletins\u2014Obstetrics; Committee on Genetics; Society for Maternal-Fetal Medicine","author":"Rose","year":"2020","journal-title":"Screening for Fetal Chromosomal Abnormalities. Obstet Gynecol"},{"issue":"1","key":"2021022616411911100_R2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.AOG.0000194186.34664.a9","article-title":"Incorporating first-trimester Down syndrome studies into prenatal screening: executive summary of the National Institute of Child Health and Human Development workshop","volume":"107","author":"Reddy","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"11","key":"2021022616411911100_R3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7110","article-title":"First and second trimester antenatal screening for Down\u2019s syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS)","volume":"7","author":"Wald","year":"2003","journal-title":"Health Technol Assess"},{"issue":"2 Pt 1","key":"2021022616411911100_R4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.AOG.0000195061.48747.f4","article-title":"Comparing three screening strategies for combining first- and second-trimester Down syndrome markers","volume":"107","author":"Palomaki","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"19","key":"2021022616411911100_R5","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa043693","article-title":"First-trimester or second-trimester screening, or both, for Down\u2019s syndrome","volume":"353","author":"Malone","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"2021022616411911100_R6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009925","article-title":"Second trimester serum tests for Down\u2019s Syndrome screening","volume":"2012","author":"Alldred","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2021022616411911100_R7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.siny.2017.10.006","article-title":"Screening for fetal chromosomal and subchromosomal disorders","volume":"23","author":"Harris","year":"2018","journal-title":"Semin Fetal Neonatal Med"},{"issue":"1","key":"2021022616411911100_R8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ogc.2017.10.001","article-title":"Cell-free DNA screening for aneuploidy and microdeletion syndromes","volume":"45","author":"Shaffer","year":"2018","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"2","key":"2021022616411911100_R9","doi-asserted-by":"crossref","first-page":"137e131","DOI":"10.1016\/j.ajog.2012.05.021","article-title":"Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18","volume":"207","author":"Norton","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"17","key":"2021022616411911100_R10","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa1407349","article-title":"Cell-free DNA analysis for noninvasive examination of trisomy","volume":"372","author":"Norton","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"2021022616411911100_R11","doi-asserted-by":"crossref","DOI":"10.1186\/s40246-019-0250-2","article-title":"Noninvasive prenatal testing for chromosome aneuploidies and subchromosomal microdeletions\/microduplications in a cohort of 42,910 single pregnancies with different clinical features","volume":"13","author":"Chen","year":"2019","journal-title":"Hum Genomics"},{"issue":"3","key":"2021022616411911100_R12","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1097\/AOG.0000000000001051","article-title":"Committee Opinion No. 640: cell-free DNA screening for fetal aneuploidy","volume":"126","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"10","key":"2021022616411911100_R13","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/gim.2016.97","article-title":"Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics","volume":"18","author":"Gregg","year":"2016","journal-title":"Genet Med"},{"issue":"1","key":"2021022616411911100_R14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5055\/ajdm.2014.0142","article-title":"Obstetrical care and women\u2019s health in the aftermath of disasters: the first 14 days after the 2010 Haitian earthquake","volume":"9","author":"Goodman","year":"2014","journal-title":"Am J Disaster Med"},{"issue":"1","key":"2021022616411911100_R15","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2019.34.e8","article-title":"Accessibility of prenatal care can affect inequitable health outcomes of pregnant women living in obstetric care underserved areas: a nationwide population-based study","volume":"34","author":"Kwak","year":"2019","journal-title":"J Korean Med Sci"},{"issue":"2","key":"2021022616411911100_R16","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1503\/cmaj.150223","article-title":"Differences in obstetric care among nulliparous First Nations and non-First Nations women in British Columbia, Canada","volume":"188","author":"Riddell","year":"2016","journal-title":"CMAJ"},{"issue":"6","key":"2021022616411911100_R17","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/jgc4.1165","article-title":"Variations in prenatal screening in a US federal healthcare system: same coverage, different options","volume":"28","author":"Thagard","year":"2019","journal-title":"J Genet Couns"},{"author":"CNN","key":"2021022616411911100_R18","article-title":"Guantanamo Bay Naval Station Fast Facts"},{"author":"United States Navy","key":"2021022616411911100_R19","article-title":"Our History"},{"author":"United States Navy. U.S. Navy Hospital Guantanamo Bay","key":"2021022616411911100_R20"},{"issue":"2","key":"2021022616411911100_R21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cll.2016.01.008","article-title":"Cost-effectiveness of old and new technologies for aneuploidy screening","volume":"36","author":"Sinkey","year":"2016","journal-title":"Clin Lab Med"},{"issue":"13","key":"2021022616411911100_R22","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1080\/14767058.2016.1214702","article-title":"Prenatal screening costs at a large military treatment facility","volume":"30","author":"Shiv","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2021022616411911100_R23","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-12-434","article-title":"Predicting costs of care in heart failure patients","volume":"12","author":"Smith","year":"2012","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"2021022616411911100_R24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/ejhg.2011.246","article-title":"Rare chromosome abnormalities, prevalence and prenatal diagnosis rates from population-based congenital anomaly registers in Europe","volume":"20","author":"Wellesley","year":"2012","journal-title":"Eur J Hum Genet"},{"author":"Defense Health Agency Website. Rates and Reimbursement","key":"2021022616411911100_R25"},{"volume-title":"The Cost of a Military Person Year: A Method for Computing Savings from Force Reductions","year":"2007","author":"Dahlman","key":"2021022616411911100_R26"},{"issue":"5","key":"2021022616411911100_R27","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/AOG.0b013e3181da93da","article-title":"First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes","volume":"115","author":"Dugoff","year":"2010","journal-title":"Obstet Gynecol"},{"issue":"5","key":"2021022616411911100_R28","doi-asserted-by":"crossref","first-page":"374e371","DOI":"10.1016\/j.ajog.2012.08.033","article-title":"Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population","volume":"207","author":"Nicolaides","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"2021022616411911100_R29","doi-asserted-by":"crossref","first-page":"727e721","DOI":"10.1016\/j.ajog.2015.12.018","article-title":"Cell-free DNA vs sequential screening for the detection of fetal chromosomal abnormalities","volume":"214","author":"Norton","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"19","key":"2021022616411911100_R30","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1080\/14767058.2016.1247800","article-title":"QUAD versus cfDNA in an urban population in the second trimester for detection of trisomy 21: a cost sensitivity analysis.","volume":"30","author":"Crimmins","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"7","key":"2021022616411911100_R31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132313","article-title":"An economic analysis of cell-free DNA non-invasive prenatal testing in the US general pregnancy population","volume":"10","author":"Benn","year":"2015","journal-title":"PLoS One"},{"key":"2021022616411911100_R32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/0167482X.2019.1708320","article-title":"The impact of invasive prenatal testing on anxiety and sleep quality in pregnant women with a screen-positive result for aneuploidy","author":"Akbas","year":"2020","journal-title":"J Psychosom Obstet Gynaecol"},{"issue":"1","key":"2021022616411911100_R33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/AOG.0000000000000603","article-title":"Incidence of emergency department visits and complications after abortion","volume":"125","author":"Upadhyay","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"6","key":"2021022616411911100_R34","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/pd.4125","article-title":"Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening","volume":"33","author":"Chetty","year":"2013","journal-title":"Prenat Diagn"},{"issue":"10","key":"2021022616411911100_R35","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/jp.2014.102","article-title":"The utilization of circulating cell-free fetal DNA testing and decrease in invasive diagnostic procedures: an institutional experience","volume":"34","author":"Pettit","year":"2014","journal-title":"J Perinatol"},{"issue":"4","key":"2021022616411911100_R36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1363\/psrh.12044","article-title":"Abortion knowledge and experiences among U.S. servicewomen: a qualitative study","volume":"49","author":"Grindlay","year":"2017","journal-title":"Perspect Sex Reprod Health"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/186\/3-4\/e410\/36391322\/usaa375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/186\/3-4\/e410\/36391322\/usaa375.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T16:45:24Z","timestamp":1614357924000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/186\/3-4\/e410\/5979774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,30]]},"references-count":36,"journal-issue":{"issue":"3-4","published-online":{"date-parts":[[2021,2,26]]},"published-print":{"date-parts":[[2021,1,30]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usaa375","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"type":"print","value":"0026-4075"},{"type":"electronic","value":"1930-613X"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2021,1,30]]}}}